UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed b	y the Re	egistrant ⊠	
Filed b	oy a Part	y other than the Registrant \Box	
Check	the appi	ropriate box:	
	Prelin	ninary Proxy Statement	
	Confi	idential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))	
	Defin	itive Proxy Statement	
\boxtimes	Defin	itive Additional Materials	
	Solici	ting Material Pursuant to §240.14a-12	
		Protalix BioTherapeutics, Inc.	
		(Name of Registrant as Specified In Its Charter)	
		(c. unic of region unit as operated in the state)	
		(Name of Person(s) Filing Proxy Statement, if other than the Registrant)	
Dayme	ont of Eil	ing Fee (Check the appropriate box):	
rayine	:111 01 1 11	ing fee (Check the appropriate box).	
\boxtimes	No fe	No fee required.	
	Fee co	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.	
	1)	Title of each class of securities to which transaction applies:	
	2)	Aggregate number of securities to which transaction applies:	
	3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set	
		forth the amount on which the filing fee is calculated and state how it was determined):	
	4)	Proposed maximum aggregate value of transaction:	
	5)	Total fee paid:	
	Fee p	e paid previously with preliminary materials.	
	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing:		
	1)	Amount Previously Paid:	
	2)	Form, Schedule or Registration Statement No:	
	3)	Filing Party:	
	4)	Date Filed:	



200 Broadacres Drive, 3rd Floor Bloomfield, NJ 07003 P: 973.873.7700 F: 973.338.1430 www.allianceadvisors.com

November 8, 2019

Urgent

Re: Your Investment in Protalix Biotherapeutics Inc.

Melissa Careson

Dear Stockholder,

We have been unable to reach you regarding an important matter relating to your investment with Protalix Biotherapeutics.

As of the date of this letter our records indicate your vote has not yet been received for the Special Meeting of Stockholders which is scheduled to be held on December 9, 2019.

The fastest and most convenient way to vote your shares is to call **833-786-6488** between the hours of 9:00 a.m. - 10:00 p.m. Eastern Time Monday through Friday and 10:00am – 6:00pm Eastern Time Saturday & Sunday in order speak with one of our proxy specialists.

Alliance Advisors has been retained by Protalix Biotherapeutics to contact you regarding this matter.

Sincerely,

Melissa Carlson Vice President

> The Shareholder Communication Strategists Copyright © 2019 by Alliance Advisors, LLC. ALL RIGHTS RESERVED